Bayer says to outsource some aspects of pharma business in Africa
Bayer will hand over the warehousing, distribution and sales representation of the medicines business, including for oncology and ophthalmology, to an unidentified third company beginning in May, it said.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-04 09:45 GMT | Update On 2024-03-22 10:16 GMT
Nairobi: Germany's Bayer will contract a third party to distribute its pharmaceutical products in four African markets including Kenya, it said, adding that the impact on jobs will be minimal.
The company, which has 200 employees in the region, said the move that targets Kenya, Ethiopia, Nigeria and Ghana, will not impact its crop science division, which makes up 90 per cent of the business.
Bayer will hand over the warehousing, distribution and sales representation of the medicines business, including for oncology and ophthalmology, to an unidentified third company beginning in May, it said.
The company did not say how many jobs would be affected, saying the process of identifying those roles was ongoing.
The move mirrors that of Britain's GSK, which said in late 2022 it would switch to a third-party distribution model for its medicines and vaccines in Kenya, and close down its commercial organisation in the East African nation.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd